A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia

Weekly administration of an anti-CD38 antibody induced elevated platelet counts in 21 of 22 patients with refractory ITP. The main adverse events were infusion reactions.

​   The New England Journal of Medicine: Search Results in Hematology/Oncology